Literature DB >> 34781255

Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient.

Flavia Chechi1, Paola Corsi2, Dario Bartolozzi2, Giovanni Gaiera3, Alessandro Bartoloni1,2,4, Lorenzo Zammarchi1,2,4.   

Abstract

The management of visceral leishmaniasis (VL) in HIV-infected patients is complex because of high mortality rates, toxic drug-related side effects, and a high risk of treatment failure and relapse. We report a case of active chronic VL in an HIV-1-infected woman presenting multiple secondary VL episodes over 7 years leading to massive splenomegaly and blood transfusion-dependent anemia despite several treatment courses and secondary prophylaxis. The patient was finally successfully treated with rescue treatment based on intravenous pentamidine. Twenty months after discontinuation of pentamidine the patient presented complete clinical and parasitological response. In patients with active chronic VL, treatment with intravenous pentamidine can be effective and should be considered as rescue treatment.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34781255      PMCID: PMC8832899          DOI: 10.4269/ajtmh.21-0600

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients.

Authors:  N Bourgeois; P Bastien; J Reynes; A Makinson; I Rouanet; L Lachaud
Journal:  HIV Med       Date:  2010-11       Impact factor: 3.180

2.  The role of splenectomy in HIV-infected patients with relapsing visceral leishmaniasis.

Authors:  J Troya; A Casquero; G Muñiz; M L Fernández-Guerrero; M Górgolas
Journal:  Parasitology       Date:  2006-12-11       Impact factor: 3.234

3.  Parasitic central nervous system infections in immunocompromised hosts: clarification of malaria diagnosis.

Authors:  William M Stauffer; Alan Magill; Kevin C Kain
Journal:  Clin Infect Dis       Date:  2006-07-01       Impact factor: 9.079

Review 4.  Visceral leishmaniosis in immunocompromised host: an update and literature review.

Authors:  Pasquale Pagliano; Silvano Esposito
Journal:  J Chemother       Date:  2017-05-10       Impact factor: 1.714

Review 5.  Neurological manifestations of human leishmaniasis.

Authors:  Alejandro Llanos-Cuentas; Braulio M Valencia; Christine A Petersen
Journal:  Handb Clin Neurol       Date:  2013

6.  Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.

Authors:  Nathalie Trudel; Ravendra Garg; Nadine Messier; Shyam Sundar; Marc Ouellette; Michel J Tremblay
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

7.  Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  Naomi Aronson; Barbara L Herwaldt; Michael Libman; Richard Pearson; Rogelio Lopez-Velez; Peter Weina; Edgar M Carvalho; Moshe Ephros; Selma Jeronimo; Alan Magill
Journal:  Clin Infect Dis       Date:  2016-11-14       Impact factor: 9.079

8.  Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.

Authors:  Matteo Piccica; Filippo Lagi; Alessandro Bartoloni; Lorenzo Zammarchi
Journal:  J Travel Med       Date:  2021-08-27       Impact factor: 8.490

9.  Unmasking cryptococcal meningitis immune reconstitution inflammatory syndrome in pregnancy induced by HIV antiretroviral therapy with postpartum paradoxical exacerbation.

Authors:  Reuben Kiggundu; Joshua Rhein; David B Meya; David R Boulware; Nathan C Bahr
Journal:  Med Mycol Case Rep       Date:  2014-05-29

10.  The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.

Authors:  Charles Abongomera; Ermias Diro; Florian Vogt; Achilleas Tsoumanis; Zelalem Mekonnen; Henok Admassu; Robert Colebunders; Rezika Mohammed; Koert Ritmeijer; Johan van Griensven
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.